A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer.

We have evaluated the feasibility of an increase in dose intensity of the cisplatin, epidoxorubicin and cyclophosphamide (PEC) regimen, with granulocyte colony-stimulating factor (G-CSF) support, in 22 patients with advanced ovarian cancer. Twenty-one patients (95.4%) received six cycles of treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Pronzato, P., Bertelli, G., Vigani, A., Vaira, F.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074481/
https://www.ncbi.nlm.nih.gov/pubmed/8645591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074481/
https://www.ncbi.nlm.nih.gov/pubmed/8645591

Ejemplares similares